Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03839446
Title Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Michael Boyiadzis

acute myeloid leukemia


Etoposide + Gemtuzumab ozogamicin + Mitoxantrone

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.